Literature DB >> 32124206

Dapagliflozin in patients with heart failure and reduced ejection fraction.

Giorgio Colombo1, Rosa Casella2, Alessia Cazzaniga2, Chiara Casiraghi2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32124206     DOI： 10.1007/s11739-020-02297-0

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  5 in total

Review 1.  Impact of Funding Source on Clinical Trial Results Including Cardiovascular Outcome Trials.

Authors:  Haris Riaz; Sajjad Raza; Muhammad Shahzeb Khan; Irbaz Bin Riaz; Richard A Krasuski
Journal:  Am J Cardiol       Date:  2015-10-09       Impact factor: 2.778

Review 2.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review.

Authors:  Subodh Verma; John J V McMurray
Journal:  Diabetologia       Date:  2018-08-22       Impact factor: 10.122

3.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  John J V McMurray; Scott D Solomon; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Inder S Anand; Jan Bělohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andrej Dukát; Junbo Ge; Jonathan G Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Mark C Petrie; Pham N Vinh; Morten Schou; Sergey Tereshchenko; Subodh Verma; Claes Held; David L DeMets; Kieran F Docherty; Pardeep S Jhund; Olof Bengtsson; Mikaela Sjöstrand; Anna-Maria Langkilde
Journal:  N Engl J Med       Date:  2019-09-19       Impact factor: 91.245

4.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

5.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

Authors:  Bernard Zinman; Christoph Wanner; John M Lachin; David Fitchett; Erich Bluhmki; Stefan Hantel; Michaela Mattheus; Theresa Devins; Odd Erik Johansen; Hans J Woerle; Uli C Broedl; Silvio E Inzucchi
Journal:  N Engl J Med       Date:  2015-09-17       Impact factor: 91.245
  5 in total
  1 in total

Review 1.  Four pillars of heart failure: contemporary pharmacological therapy for heart failure with reduced ejection fraction.

Authors:  Sam Straw; Melanie McGinlay; Klaus K Witte
Journal:  Open Heart       Date:  2021-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.